Buscar
Monopar Therapeutics Inc
MNPRAñadir a la lista de seguimiento
110.450USD
+0.580+0.53%
Cierre 07-27 16:00（ET）Cotizaciones retrasadas 15 min
739.91MCap. mercado
PérdidaP/E TTM
Más Datos de Monopar Therapeutics Inc Compañía
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Información de Monopar Therapeutics Inc
Símbolo de cotizaciónMNPR
Nombre de la empresaMonopar Therapeutics Inc
Fecha de salida a bolsaDec 19, 2019
Director ejecutivoRobinson (Chandler D)
Número de empleados16
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 19
Dirección1000 Skokie Blvd Ste 350
CiudadWILMETTE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal60091-1146
Teléfono18473880349
Sitio Webhttps://www.monopartx.com/
Símbolo de cotizaciónMNPR
Fecha de salida a bolsaDec 19, 2019
Director ejecutivoRobinson (Chandler D)
Ejecutivos de Monopar Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
162.08K
+5.42%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
15.05K
-6.64%
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
8.76K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Mr. Andrew J. Cittadine
Mr. Andrew J. Cittadine
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Patrice P. Rioux, M.D., Ph.D.
Dr. Patrice P. Rioux, M.D., Ph.D.
Acting Chief Medical Officer
Acting Chief Medical Officer
--
--
Mr. Vu Quan
Mr. Vu Quan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
162.08K
+5.42%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
15.05K
-6.64%
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
8.76K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Monopar Therapeutics Inc?
Los cinco principales accionistas de Monopar Therapeutics Inc son: Dr. Chandler D. Robinson, M.D.
¿Cuántas instituciones poseen acciones de Monopar Therapeutics Inc (MNPR)?
A fecha de 2026Q1, 147 instituciones poseen acciones de Monopar Therapeutics Inc, con un valor de mercado combinado de aproximadamente 5.90M, lo que representa el 88.03% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1082274.00.